AIM ImmunoTech Tackles Post-COVID Fatigue
AIM ImmunoTech (NYSE American: AIM) has reported positive topline results from a Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue.
AIM Chief Executive Officer Thomas K. Equels said, “I’m very much encouraged by these results and the fact that the Ampligen group outperformed the placebo group in PROMIS® measures of fatigue in 12 of the 13 weeks tracked. Ampligen’s positive impact on the objective six-minute walk test is also very encouraging and useful for future trial design. This promising initial data helps solidify our belief that AIM is on the right path with the development of Ampligen for the Post-COVID condition of fatigue. Also as expected, Ampligen was generally well tolerated in this indication.”
The AMP-518 clinical trial was a two-arm, randomized, double-blind, placebo-controlled, multicenter study. 80 subjects were enrolled in the study, in which Ampligen was generally well-tolerated with no severe adverse events.
An analysis of a number of endpoints found that the difference in change from baseline in PROMIS® Fatigue Score between the Ampligen and placebo groups reached or approached statistical significance at several time points during the treatment phase. The Six-Minute Walk Test also revealed a higher impact of Ampligen on distance traveled in six minutes at Week 13 compared to placebo.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.